Owens & Minor, Inc. Hits New 52-Week Low at $4.35

Owens & Minor, Inc., a microcap player in the Pharmaceuticals & Biotechnology industry, has reached a new 52-week low of USD 4.35 on October 10, 2025. This significant decline reflects a challenging year for the company, with a staggering 73.66% drop in its stock price over the past year, contrasting sharply with the S&P 500's positive performance of 13.36% during the same period.
The company's financial metrics reveal a P/E ratio of 6.00, indicating a low valuation relative to earnings. However, Owens & Minor's financial health raises concerns, highlighted by a negative Return on Equity of -76.43% and a Debt to Equity ratio of -7.06, suggesting difficulties in managing debt. The stock's Price to Book ratio stands at -1.48, further emphasizing its current valuation challenges.

Despite a 20.30% compound annual growth rate in operating profits over the last five years, the company has struggled with profitability, as evidenced by a low Return on Capital Employed of 11.05%. The recent performance metrics indicate a need for strategic reassessment as the company navigates its current market position.